FOXO3 and breast carcinoma: To determine whether GRP78-AKT1-mediated downregulation of FOXO3a is responsible for ΔNp63α transcription and cell migration, we treated GRP78-overexpressing HCC1806 cells with MK2206, a phase II AKT inhibitor used in breast cancer treatment.